1. Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians

3. Many Adults With CVD Treated With High-Intensity Statins Are Not Achieving Recommended LDL-C Levels

4. PINNACLE: Rates of LLT Use Among Patients With LDL-C ≥ 190 mg/dL

5. PCSK9 Inhibitor CV Outcomes Trials

6. FOURIER CV Outcomes

7. ODYSSEY CV Outcomes

8. ODYSSEY Subgroup With Baseline LDL-C ≥ 100 mg/dL

9. ICER Alirocumab Effectiveness and Value

10. PCSK9 Inhibitor Valuation

11. PCSK9 Inhibitor Safety Data

12. Patients Who May Benefit From PCSK9 Inhibitor Therapy 2017 Focused Update of 2016 ACC Expert Consensus Decision Pathway on Role of Non-Statin Therapies

13. FOCUS: PCSK9 Inhibitor Rejection Rate in Patients With FH or ASCVD

14. CV Risk in Patients Denied PCSK9 Inhibitor Therapy

15. 2017 Focused Update of 2016 ACC Expert Consensus Decision Pathway: Role of Nonstatin Therapies in LDL-C Lowering

16. Tools for Assisting PCSK9 Inhibitor Access

17. Barriers to PSCK9 Inhibitor Access

18. Navigating the Prior Authorization Process Clinical Pearls

19. Universal Guidance for Improving Access to PCSK9 Inhibitors

20. Team-Based Care

21. AHA Diagnostic Criteria for FH in Adults

22. FH Foundation Guidance: Prior Authorization Criteria for PCSK9 Inhibitors for FH Treatment in Adults

23. Case: 65-Year-Old Man With CAD Post-CABG

24. Case: 65-Year-Old Man With CAD Post-CABG (cont) Initial Treatment Plan

25. Case: 65-Year-Old Man With CAD Post-CABG (cont) Muscle Symptoms With Atorvastatin

26. Case: 65-Year-Old Man With CAD Post-CABG (cont) Rosuvastatin Intolerability

27. Patient Education PCSK9 Inhibitor Therapy

28. Patient Education Correct Injecting Procedure

29. Summary

30. Abbreviations

31. Abbreviations (cont)